基于小波高频距离像的红外小目标检测

针对远距离复杂背景下红外小目标检测问题,本文提出了一种基于小波高频距离像的方法。该方法首先将处理空间变换到小波域,通过分析残留背景、目标和噪声系数在高频子带的差异,定义基于邻域均值的子带系数表达形式,构造高频子带系数的中心向量,对小波高频图像进行综合形成距离像,得到红外复杂背景的抑制结果。在此基础上,利用恒虚警率算法将单帧背景抑制图像分割成候选目标、残留背景和噪声像素点。最后,在时间域基于目标运动的相关性,利用管道滤波实现红外小目标的最终检测。仿真实验结果表明,相对于经典算法,本文方法可以实现对红外复杂背景的有效抑制,增强目标信号的强度,准确稳定的从红外复杂背景中检测出小目标。     

地面积水与装甲目标毫米波被动探测信号差异研究

以往毫米波被动探测中以平面金属目标代替立体金属目标(如装甲目标),而平面金属目标的探测信号又和地面积水的探测信号非常相似,所以导致这三种目标难以分辨。针对这一问题,从毫米波被动探测平面金属、积水、装甲目标探测信号的基本理论出发,通过建立目标模型、推导天线温度计算模型,仿真得到了这三种目标的探测信号,查找信号差异并分析总结了造成差异的根源。仿真结果证实了分析的正确性和有效性,为地面装甲目标识别算法的研究提供了必要的理论支撑和分析依据。     

一种改进的三帧差分运动目标实时检测算法

针对传统的三帧差分法提取的运动目标存在大量的噪声和空洞,提出了一种改进的三帧差分运动目标实时检测算法。该算法采用Surendra背景提取算法提取有效背景,对视频流中连续的三帧图像分别进行背景减除,得到的结果作为反馈对背景进行选择性更新,利用HSV颜色空间去除阴影后进行三帧差分,将差分结果进行“与”运行,通过将中间帧背景减除结果与“与”运算的结果进行“或”运算,这样可以得到运动目标的完整信息。实验结果表明,该算法能够快速、完整、准确地检测出运动目标,可有效应用于实时监控系统。     

黑腔冷冻靶传热与自然对流的数值模拟研究

惯性约束聚变的设计要求在靶丸内形成均匀光滑的氘氚冰层, 靶丸周围的热环境对冰层的质量特别是低阶粗糙度有很大的影响. 本文对自主研发的黑腔冷冻靶实验装置中的热物理问题展开了数值模拟, 重点考察了黑腔冷冻靶的传热和流体力学特性. 通过参数分析得到了自然对流对靶丸温度均匀性产生影响的临界条件. 比较了黑腔不同布置朝向时的流场和温度分布, 结果显示黑腔水平布置时自然对流更加强烈, 造成的靶丸温度不均匀性也更大. 在此基础上, 讨论了消除自然对流影响的可能性, 结果发现仅当黑腔垂直布置时利用黑腔分区方法能够消除对流效应对靶丸温度不均匀性的影响而黑腔水平布置时不能消除. 研究结论对于实验中冷冻靶结构的设计、改进和实验的开展等具有指导意义.     

Computer-aided design and discovery of protein–protein interaction inhibitors as agents for anti-HIV therapy

Protein–protein interactions (PPI) are involved in most of the essential processes that occur in organisms. In recent years, PPI have become the object of increasing attention in drug discovery, particularly for anti-HIV drugs. Although the use of combinations of existing drugs, termed highly active antiretroviral therapy (HAART), has revolutionized the treatment of HIV/AIDS, problems with these agents, such as the rapid emergence of drug-resistant HIV-1 mutants and serious adverse effects, have highlighted the need for further discovery of new drugs and new targets. Numerous investigations have shown that PPI play a key role in the virus’s life cycle and that blocking or modulating them has a significant therapeutic potential. Here we summarize the recent progress in computer-aided design of PPI inhibitors, mainly focusing on the selection of the drug targets (HIV enzymes and virus entry machinery) and the utilization of peptides and small molecules to prevent a variety of protein–protein interactions (viral–viral or viral–host) that play a vital role in the progression of HIV infection.     

Redesigning the DNA‐Targeted Chromophore in Platinum–Acridine Anticancer Agents: A Structure–Activity Relationship Study

Platinum–acridine hybrid agents show low‐nanomolar potency in chemoresistant non‐small cell lung cancer (NSCLC), but high systemic toxicity in vivo. To reduce the promiscuous genotoxicity of these agents and improve their pharmacological properties, a modular build–click–screen approach was used to evaluate a small library of twenty hybrid agents containing truncated and extended chromophores of varying basicities. Selected derivatives were resynthesized and tested in five NSCLC cell lines representing large cell, squamous cell, and adenocarcinomas. 7‐Aminobenz[c]acridine was identified as a promising scaffold in a hybrid agent ( P1–B1 ) that maintained submicromolar activity in several of the DNA‐repair proficient and p53‐mutant cancer models, while showing improved tolerability in mice by 32‐fold compared to the parent platinum–acridine ( P1–A1 ). The distribution and DNA/RNA adduct levels produced by the acridine‐ and benz[c]acridine‐based analogues in NCI‐H460 cells (confocal microscopy, ICP‐MS), and their ability to bind G‐quadruplex forming DNA sequences (CD spectroscopy, HR‐ESMS) were studied. P1–B1 emerges as a less genotoxic, more tolerable, and potentially more target‐selective hybrid agent than P1–A1 .     

Probing the Anticancer Mechanism of (−)‐Ainsliatrimer A through Diverted Total Synthesis and Bioorthogonal Ligation

Herein, we report an efficient approach for exploring the novel anticancer mechanism of (?)‐ainsliatrimer A, a structurally complex and unique trimeric sesquiterpenoid, through a combined strategy of diverted total synthesis (DTS) and bioorthogonal ligation (TQ ligation), which allowed us to visualize the subcellular localization of this natural product in live cells. Further biochemical studies facilitated by pretarget imaging revealed that PPARγ, a nucleus receptor, was a functional cellular target of ainsliatrimer A. We also confirmed that the anticancer activity of ainsliatrimer A was caused by the activation of PPARγ.     

冠状病毒抑制剂的研究进展

冠状病毒是一类广泛存在且对人及家畜具有严重危害的病原体,其中于2003年全球爆发的严重急性呼吸综合征病毒(SARS-CoV)以及2012年被发现并传播的中东呼吸综合征病毒(MERS-CoV)给人们的生命健康以及全球经济造成了严重威胁以及重大损失,特别是2019年末爆发的新型冠状病毒(SARS-CoV-2),截至目前为止已经造成了几百万的感染病例以及几十万人的死亡。可以看出,冠状病毒具有较高的传播性以及较高的致死率,时刻威胁着人们的健康安全,但是针对冠状病毒的感染目前还没有批准上市的有效药物,也没有用于预防的疫苗。本文围绕目前关于冠状病毒的潜在成药性靶点,详细介绍了针对这些靶点的具有代表性的抑制剂的结构设计及其化学合成方法,以期为目前抗冠状病毒药物的研发提供一些参考。     

Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid

Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disease arising from mutations in the dystrophin gene. Upregulation of utrophin to compensate for the missing dystrophin offers a potential therapy independent of patient genotype. The first‐in‐class utrophin modulator ezutromid/SMT C1100 was developed from a phenotypic screen through to a Phase 2 clinical trial. Promising efficacy and evidence of target engagement was observed in DMD patients after 24 weeks of treatment, however trial endpoints were not met after 48 weeks. The objective of this study was to understand the mechanism of action of ezutromid which could explain the lack of sustained efficacy and help development of new generations of utrophin modulators. Using chemical proteomics and phenotypic profiling we show that the aryl hydrocarbon receptor (AhR) is a target of ezutromid. Several lines of evidence demonstrate that ezutromid binds AhR with an apparent K_D of 50 nm  and behaves as an AhR antagonist. Furthermore, other reported AhR antagonists also upregulate utrophin, showing that this pathway, which is currently being explored in other clinical applications including oncology and rheumatoid arthritis, could also be exploited in future DMD therapies.     

Inverse screening of Simvastatin kinase targets from glioblastoma druggable kinome

The statin drug Simvastatin is a HMG-CoA reductase inhibitor that has been widely used to lower blood lipid. However, the drug is clinically observed to reposition a significant suppressing potency on glioblastoma (GBM) by unexpectedly targeting diverse kinase pathways involved in GBM tumorigensis. Here, an inverse screening strategy is described to discover potential kinase targets of Simvastatin. Various human protein kinases implicated in GBM are enriched to define a druggable kinome; the binding behavior of Simvastatin to the kinome is profiled systematically via an integrative computational approach, from which most kinases have only low or moderate binding potency to Simvastatin, while only few are identified as promising kinase hits. It is revealed that Simvastatin can potentially interact with certain known targets or key regulators of GBM such as ErbB, c-Src and FGFR signaling pathways, but exhibit low affinity to the well-established GBM target of PI3K/Akt/mTOR pathway. Further assays determine that Simvastatin can inhibit kinase hits EGFR, MET, SRC and HER2 at nanomolar level, which are comparable with those of cognate kinase inhibitors. Structural analyses reveal that the sophisticated T790 M gatekeeper mutation can considerably reduce Simvastatin sensitivity to EGFR by inducing the ligand change between different binding modes.